{"filings":[{"id":1083956,"accession_number":"0001140361-26-025440","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2026-06-16T20:11:35+00:00","items":["7.01","9.01"],"status":"ready","headline":"Opus Genetics details five IRD gene therapy programs; four data readouts expected in 2027, cash runway to 2029","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["OPGx-RDH12 enters clinical testing in Q4 2026; OPGx-MERTK Q1 2027; OPGx-RHO H2 2027.","OPGx-LCA5 Phase 3 dosing expected Q4 2026; OPGx-BEST1 topline data from Cohort 1 due September 2026.","Four clinical data readouts from across the pipeline expected in 2027.","Cash runway into 2029 expected to fund multiple clinical inflection points and potential product approvals.","Global IRD prevalence estimates provided: RDH12 ~30,900, MERTK ~21,960, RHO ~30,200, LCA5 ~3,240, BEST1 ~21,800 patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1074156,"accession_number":"0001140361-26-025363","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2026-06-16T16:05:48+00:00","items":["7.01","9.01"],"status":"ready","headline":"Opus Genetics holds R&D Science Forum; presentation content not disclosed in filing excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company delivered a corporate presentation at its Virtual R&D Science Forum on June 16, 2026.","Presentation is accessible via the investor relations section of the company's website.","No specific pipeline data, financials, or material updates from the presentation are included in the filing excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22245,"accession_number":"0001628280-26-033856","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2026-05-12T11:01:41+00:00","items":["2.02","9.01"],"status":"ready","headline":"Opus Genetics Q1 net loss $65.5M; cash $60M; enters $35M Oberland debt facility","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $65.5M ($0.75 per share) vs $8.2M loss a year ago; includes non-cash warrant liability fair value change.","Revenue $2.2M from Viatris collaboration, down from $4.4M.","Cash $60M at March 31; post-quarter $35M senior secured notes from Oberland Capital plus $5M equity; total ~$90M funds into 2029.","LCA5 program accepted into FDA's RDEP program; pivotal Phase 3 enrollment ongoing, dosing expected Q4 2026.","BEST1 Cohort 1 topline data expected September 2026; R&D Science Forum June 16."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":2157000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91768,"accession_number":"0001140361-26-016764","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["2.03"],"status":"ready","headline":"Opus Genetics closes $35 million initial tranche of $155 million senior secured notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $35 million tranche funded on April 21, 2026; notes mature April 21, 2033.","Notes bear floating rate based on Term SOFR (with floor) plus margin; interest payable quarterly.","Total note purchase agreement provides up to $155 million ($105M committed, $50M uncommitted).","Notes secured by substantially all assets of Opus Genetics and its subsidiaries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91767,"accession_number":"0001140361-26-015990","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Opus Genetics stockholders approve doubling authorized shares to 250M at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stock increase proposal passed: 45,360,642 for, 1,486,247 against, 429,479 abstentions.","Say-on-pay approved with 34,862,743 votes for, 259,749 against, 110,779 abstentions.","All nine board nominees elected, each receiving over 33.8M votes for.","Ernst & Young ratified as independent auditor for FY 2026.","Meeting held April 20, 2026; all proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91766,"accession_number":"0001140361-26-013481","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Opus Genetics enters change-in-control bonus agreements with four top executives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreements cover CEO Dr. George Magrath, CFO Robert Gagnon, COO Joseph Schachle, CS&DO Dr. Ashwath Jayagopal.","Each agreement provides a gross-up payment for any excise tax under Section 4999 of the Code triggered by change of control.","Agreements were entered into on April 1, 2026; form filed as Exhibit 10.1.","Gross-up is designed to put executives in the same after-tax position as if the excise tax had not applied."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91765,"accession_number":"0001140361-26-013394","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Opus Genetics secures up to $155M debt facility from Oberland Capital; cash runway extended into 2029","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$155M senior secured notes: $35M initial (closing Apr 20, 2026), $35M option in 12 mos, $35M milestone-based (LCA5), $50M mutual agreement.","$5M equity investment at $4.48/share; 1,116,070 shares issued to Oberland affiliates.","Notes mature Apr 2033; floating rate (SOFR + margin, 3.68% floor); 50% PIK first 8 quarters; 10% convertible at $6.72/share.","Cash ~$100M including initial funding; runway extended into 2029 through pivotal studies and potential approvals.","Pipeline acceleration: OPGx-RDH12 (Q4 2026), OPGx-MERTK (end 2026), OPGx-RHO (2027) entering clinic."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102080,"accession_number":"0001140361-26-008621","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Opus Genetics reports FY2025 net loss $49.6M; cash $70.1M; PDUFA date Oct 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $49.6M ($0.80/sh) vs $57.5M ($2.15/sh) in 2024; revenue $14.2M from Viatris collab.","Cash $45.1M at Dec 31, 2025; raised $25M in private placement to $70.1M; runway into H1 2028.","BEST1 gene therapy: sentinel patient showed 12-letter BCVA gain and 23% CST decrease; three-month data from full cohort expected mid-2026.","FDA set PDUFA date Oct 17, 2026 for Phentolamine Ophthalmic Solution 0.75% for presbyopia.","Phase 3 LCA5 trial enrolling; RDEP review submission planned Q1 2026; MERTK funding secured from Abu Dhabi fund."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102079,"accession_number":"0001140361-26-006176","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["1.01","2.02","3.02","5.03","8.01","9.01"],"status":"ready","headline":"Opus Genetics raises $25M via Series B convertible preferred; pro forma cash $70M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed private placement of 7,374,632 shares of Series B Non-Voting Convertible Preferred at $3.39/share for $25M.","Proceeds to advance gene therapy clinical programs, working capital, and general corporate purposes.","Preliminary cash balance $45M as of Dec 31, 2025; pro forma $70M after private placement proceeds.","Conversion to common stock requires stockholder approval at 2026 annual meeting; filing of Certificate of Designation.","Company entered into Registration Rights Agreement to register resale of conversion shares by April 19, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102078,"accession_number":"0001140361-26-000913","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Opus Genetics to present at J.P. Morgan Healthcare Conference; no substantive details in filing exhibit","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Management will present at 44th Annual J.P. Morgan Healthcare Conference on Jan 15, 2026 at 8:15 a.m. PT.","Presentation attached as Exhibit 99.1, but exhibit text is incomplete and lacks specific data.","No new financial or pipeline information disclosed in the Form 8-K filing.","Webcast available via investor relations section of company website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102077,"accession_number":"0001140361-26-000615","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Opus Genetics details 2025 progress and 2026 catalysts; cash >$50M, sNDA for presbyopia submitted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["sNDA submitted for phentolamine 0.75% (presbyopia); FDA decision expected by end of 2026.","BEST1 Phase 1/2 initial data this quarter at Macula Society; Cohort 1 3-month results mid-2026.","LCA5 Phase 3 pivotal trial dosing expected in H2 2026 after run-in enrollment.","Cash and equivalents >$50M following $23M equity raise; runway into H2 2027.","One to two preclinical IRD programs (RHO, CNGB1, MERTK, RDH12-LCA, NMNAT1) targeting clinical entry in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118420,"accession_number":"0001140361-25-046187","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Opus Genetics partner Viatris files sNDA with FDA for presbyopia treatment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Viatris filed sNDA for Phentolamine Ophthalmic Solution 0.75% to treat presbyopia.","sNDA supported by positive VEGA-3 Phase 3 results confirming efficacy, safety, durability.","No assurance FDA will accept sNDA or complete review on anticipated timeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118419,"accession_number":"0001140361-25-041544","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Opus Genetics Q3 net loss $17.5M; cash >$50M; LCA5 gene therapy gains FDA RMAT","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss of $17.5M ($0.25/sh) vs $7.5M ($0.29/sh) in prior year; revenue $3.1M from Viatris collaboration.","Cash $30.8M at Sep 30; raised $23M post-quarter; total >$50M expected to fund into H2 2027.","Positive LCA5 data: 3-month pediatric and 18-month adult gains in cone-mediated vision; FDA RMAT meeting supports accelerated approval pathway.","BEST1 gene therapy trial recruiting; initial data Q1 2026. Phentolamine sNDA for presbyopia planned by year-end 2025.","Non-dilutive funding: $1.6M from RDH12 Alliance and $2M from Retinal Degeneration Fund for MERTK program."],"consensus_eps_estimate":-0.1313,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":10331000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118418,"accession_number":"0001140361-25-040796","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Opus Genetics raises ~$23M in registered direct offering with Perceptive, Nantahala, Balyasny","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Purchase agreement with affiliates of Perceptive, Nantahala, and Balyasny for 3.83M shares and 7.18M pre-funded warrants at $2.09/$2.0899.","Gross proceeds ~$23M; net proceeds to advance LCA5 and BEST-1 gene therapy programs and for working capital.","Pre-funded warrants exercisable at $0.0001/share, subject to 4.99%/9.99% beneficial ownership limitation.","Closing expected November 7, 2025; no placement agent or underwriting discounts.","Offering registered on Form S-3; customary closing conditions remain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118417,"accession_number":"0001140361-25-040675","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Opus Genetics raises $23M in direct offering and secures FDA guidance for LCA5 gene therapy trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$23M registered direct offering led by Perceptive Advisors and Balyasny Asset Management; closes Nov 7, 2025.","Offering: 3.83M shares at $2.09/sh and pre-funded warrants for 7.18M shares at $2.0899.","FDA RMAT meeting provides guidance on registration strategy; Phase 3 design adaptive, as few as 8 participants.","Phase 1/2 data: all 6 late-stage participants achieved clinically meaningful vision improvements.","First participant enrolled in run-in; dosing H2 2026, topline ~1 year later; cash runway into H2 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134854,"accession_number":"0001140361-25-036637","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Opus Genetics LCA5 gene therapy shows 0.3 logMAR improvement in pediatric cohort; durable 18-month adult data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three pediatric participants (ages 16-17) showed group avg 0.3 logMAR visual acuity improvement and >1 log unit cone sensitivity improvement on FST.","All three pediatric participants improved on mobility test; microperimetry showed improved fixation in one evaluable participant.","Adult data (3 participants) show visual acuity improvements sustained through 18 months; therapy well-tolerated with no ocular SAEs.","Company expects to meet with FDA in Q4 2025 to discuss results and next steps for OPGx-LCA5 program.","No ocular serious adverse events or dose-limiting toxicities; all ocular AEs mild, anticipated, not related to study drug."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134853,"accession_number":"0001140361-25-033668","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Opus Genetics appoints Robert Gagnon as CFO effective September 2, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Annual base salary of $465,000, eligible for annual bonus up to 45% of base.","Stock option for 250,000 shares and restricted stock award for 200,000 shares, both vesting over four years.","Gagnon previously CFO of Remix Therapeutics and Verastem Oncology; has raised over $2B in capital.","Appointment is part of Opus's advancement of clinical pipeline for inherited retinal diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134852,"accession_number":"0001140361-25-032533","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Opus Genetics raises $3.5M in private placement led by board chair for gene therapy manufacturing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 3,138,338 shares at ~$1.11/sh in private placement; gross proceeds $3.5M.","Led by board chair Cam Gallagher ($1M) and lead independent director Sean Ainsworth.","Proceeds to expedite manufacturing process development for gene therapy candidates OPGx-LCA5 and OPGx-BEST1.","Private placement closed August 25, 2025; exempt under Section 4(a)(2) and Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134851,"accession_number":"0001140361-25-030822","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Opus Genetics Q2 net loss narrows to $7.4M; FDA grants RMAT for OPGx-LCA5","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.4M ($0.12/share) vs $7.8M ($0.30) in Q2 2024; revenue $2.9M from Viatris collaboration.","FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5 gene therapy.","Positive 12-month adult and early pediatric data for OPGx-LCA5; 3-month pediatric data due Q3 2025.","Phentolamine Phase 3 VEGA-3 (presbyopia) and LYNX-2 met primary endpoints; sNDA submission planned H2 2025.","Cash $32.4M expected to fund operations into H2 2026; up to $3.6M non-dilutive funding secured for RDH12 and MERTK programs."],"consensus_eps_estimate":-0.2071,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":7252000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134850,"accession_number":"0001140361-25-026853","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Opus Genetics partners with Global RDH12 Alliance for OPGx-RDH12; $1.6M funding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with RDH12 Fund for Sight and Eyes on the Future provides up to $1.6M for OPGx-RDH12 development.","Partnership includes risk-sharing structure and performance-based milestones; IND filing targeted by late 2025.","If milestones missed, Funding Parties can exercise a non-exclusive license; Opus retains right to negotiate exclusive license back.","During term, Opus cannot grant exclusive U.S. license to a third party without Funding Parties' consent.","Term ends upon dosing three patients in Phase 1a/2b or first commercial sale, or if exclusive global licensee assumes obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151788,"accession_number":"0001140361-25-023732","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Opus Genetics VEGA-3 Phase 3 trial meets primary endpoint for presbyopia treatment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["27.2% of patients on drug achieved ≥15-letter DCNVA gain vs 11.5% placebo (p<0.0001) at 12h post-dose on Day 8.","Safety profile consistent with prior trials; no treatment-related serious adverse events reported.","No evidence of tachyphylaxis over the 6-week study period.","NDA submission to FDA planned for the second half of 2025.","Cash on hand expected to fund operations into H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151787,"accession_number":"0001140361-25-023648","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Nirav Jhaveri departs Opus Genetics; Amy Rabourn appointed interim principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Nirav Jhaveri terminated without cause on June 25, 2025; no disagreement with auditors or management.","Jhaveri eligible for severance per employment agreement subject to separation release.","Amy Rabourn, SVP of Finance, serves as principal financial and accounting officer until successor appointed.","Rabourn has 20+ years finance experience, CPA, previously at Gemphire and Pfizer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151786,"accession_number":"0001140361-25-023265","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Opus Genetics gets up to $2M non-dilutive funding from RD Fund for MERTK gene therapy program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $2 million non-dilutive funding from RD Fund (Foundation Fighting Blindness) for OPGx-MERTK preclinical program.","OPGx-MERTK targets retinitis pigmentosa caused by MERTK gene mutations; no approved therapies exist.","Funding expected to support IND-enabling studies and advance gene therapy pipeline for inherited retinal diseases.","Cash runway extended into second half of fiscal year 2026, based on current projections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151785,"accession_number":"0001140361-25-023172","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Opus Genetics secures up to $2M nondilutive funding from Foundation Fighting Blindness for MERTK gene therapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $2,000,000 nondilutive funding from Foundation Fighting Blindness Retinal Degeneration Fund for MERTK gene therapy program.","$1,000,000 disbursed upfront; up to $1,000,000 additional upon milestone achievement.","Company must meet development milestones; failure triggers obligation to out-license program.","Regulatory milestone triggers payment equal to total funded amount; tiered royalties until 300% repayment.","On change of control, RDF may require buy-out at 100% of funded amounts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151784,"accession_number":"0001140361-25-019153","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Opus Genetics Q1 net loss $8.2M; cash $41.8M; LCA5 gene therapy shows sustained 12-month efficacy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.2M ($0.24 per share) vs $7.1M ($0.29) in Q1 2024.","Cash and equivalents $41.8M; management expects runway into Q2 2026.","License revenue from Viatris was $4.4M, up from $1.7M YoY, primarily R&D reimbursement.","OPGx-LCA5 Phase 1/2 data at ARVO show durable efficacy at 12 months; pediatric cohort enrollment started.","Topline data for LYNX-2 (dim light) and VEGA-3 (presbyopia) Phase 3 trials expected mid-2025 and H1 2025, respectively."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":4370000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151783,"accession_number":"0001140361-25-016948","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Opus Genetics stockholders elect nine directors and approve all proposals at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected with >21M votes for each; no withhold votes exceeded 3.1M.","Ratification of Ernst & Young as auditor for FY2025 passed with 30.2M votes for (94% of votes cast).","Advisory say-on-pay proposal approved with 20.4M votes for (86% of votes cast).","Conversion of Series A Preferred Stock into common stock approved with 16.7M votes for (84% of votes cast).","Adjournment proposal passed but deemed moot as Conversion proposal already passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151782,"accession_number":"0001140361-25-012366","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Opus Genetics terminates $50M equity purchase agreement with Lincoln Park Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Purchase Agreement with Lincoln Park Capital effective April 3, 2025.","Agreement allowed up to $50M in stock sales; company cites limited value given current market price.","Prior to termination, issued 1.7M shares for net proceeds of ~$5.2M; remaining $44.8M facility cancelled.","Registration obligations under the agreement survive termination for 90 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170651,"accession_number":"0001140361-25-011181","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Opus Genetics reports FY2024 net loss of $57.5M; gene therapy pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $57.5M ($2.15/sh) vs $10.0M in 2023; revenue $11M from Viatris license.","Cash $30.3M at year-end; March 2025 financing raised $21.5M, extending runway into H2 2026.","OPGx-LCA5 Phase 1/2 shows durable response at 12 months; Type D FDA meeting held; pediatric enrollment started.","OPGx-BEST1 IND-enabling studies done; Phase 1/2 initiation planned for 2025 with preliminary data by Q1 2026.","Phentolamine LYNX-2 (dim light) and VEGA-3 (presbyopia) Phase 3 trials fully enrolled; topline data expected mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":4370000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170650,"accession_number":"0001140361-25-010064","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Opus Genetics closes $20M public stock/warrant offering; CEO & chairman buy $1.5M unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 12,219,736 units (share + warrant) at $0.95/unit plus 8,832,895 pre-funded warrants at $0.9499; gross proceeds ~$20M.","Private placement: 1,176,471 shares and warrants at $1.275/unit to CEO Dr. George Magrath and chairman Cam Gallagher.","Public warrants exercisable at $0.95, private at $1.15; both 5-year terms, callable after OPGx-BEST1 Cohort 1 data and VWAP conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170649,"accession_number":"0001999371-25-002866","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Opus Genetics amends bylaws to enhance stockholder rights; sues Sandoz over RYZUMVI","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bylaws amended: written consent requirements eliminated; 20% threshold to call special meeting.","Stockholder removal threshold reduced to simple majority; amendment threshold also reduced to simple majority.","Filed patent infringement suit against Sandoz in NJ over ANDA for generic RYZUMVI; seeks injunction.","Suit filed with partner FamyGen Life Sciences; Opus intends to vigorously enforce RYZUMVI IP rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170648,"accession_number":"0001140361-25-009729","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Opus Genetics reports preliminary FY 2024 net loss of $56.8M, cash burn $25.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY 2024 expected to be approximately $56.8 million.","Net cash used in operating activities for FY 2024 approximately $25.6 million.","Cash and cash equivalents balance as of Dec 31, 2024 approximately $30.3 million.","All figures are preliminary, unaudited and subject to change upon finalization of audited financials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170647,"accession_number":"0001140361-25-006961","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Opus Genetics receives Sandoz Paragraph IV notice challenging six RYZUMVI patents","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Sandoz filed ANDA for generic RYZUMVI; alleges six Orange Book patents invalid/unenforceable/non-infringed.","Challenged patents: 9,795,560, 10,278,918, 10,772,829, 11,090,261, 11,844,858, and 11,400,077.","Two other RYZUMVI Orange Book patents (12,201,615 and 12,201,616) not challenged by Sandoz.","Opus or its commercial partner may file patent infringement lawsuit to defend IP rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170646,"accession_number":"0001140361-25-001899","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2025-01-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Opus Genetics amends CEO and CFO employment agreements; enhances severance upon Change in Control","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Magrath severance multiple raised to 1.5x salary+target bonus on CIC termination; COBRA extended to 18 months.","CFO Jhaveri severance multiple raised to 1.0x salary+target bonus; COBRA extended to 12 months.","Magrath also gets prorated target bonus for non-CIC qualifying termination.","Jhaveri's enhanced sever eligibility expanded to include 3 months prior to a Change in Control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170645,"accession_number":"0001140361-25-001819","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Opus Genetics sets 2025 Annual Meeting for April 30, 2025; proposal deadlines","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2025 Annual Meeting scheduled for April 30, 2025.","Deadline for stockholder proposals under Rule 14a-8 is February 2, 2025.","Advance notice deadline for director nominations is February 2, 2025.","Universal proxy rule deadline for other nominees is March 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170644,"accession_number":"0001140361-25-001013","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Opus Genetics initiates $40M ATM equity offering with Leerink Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered into ATM equity sales agreement with Leerink Partners LLC for up to $40M in common stock.","Prior ATM program with JonesTrading terminated; $26.4M had been sold under that program.","Net proceeds for general corporate purposes, including preclinical studies and clinical trials.","Leerink receives 3% commission on gross sales; Company has broad discretion over proceeds use."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170643,"accession_number":"0001140361-25-000467","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K/A","filed_at":"2025-01-07T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Opus Genetics files audited FY2023 financials of acquired Opus Inc.; net loss $9.75M, cash $180k","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["FY2023 audited: net loss $9.75M, no revenue; accumulated deficit $25.1M.","Cash & equivalents only $0.18M at Dec 31, 2023; total liabilities $2.93M exceed assets $0.79M.","R&D spending $7.18M, G&A $2.72M; convertible notes and warrant liabilities of $1.12M at fair value.","Acquisition closed Oct 22, 2024; combined company renamed Opus Genetics, Inc. (ticker IRD)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187626,"accession_number":"0001140361-24-046028","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Opus Genetics reports Q3 net loss of $7.5M; pro forma cash $37M after Opus acquisition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.5M ($0.29/share) vs net income $5.6M in Q3 2023; revenue $3.9M down from $11.9M.","Pro forma cash $37M post-merger with Opus Genetics; expects runway into 2026.","Acquisition of Opus Genetics closed Oct 22; issued 5.2M common shares and 14,145 Series A preferred.","Pipeline: four data readouts in 2025 including Phase 3 for Phentolamine in presbyopia and dim light.","Gene therapy candidate OPGx-LCA5 showed visual improvement in 3/3 adult patients; pediatric enrollment Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":6690000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187625,"accession_number":"0001140361-24-043915","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["1.01","5.03","2.01","2.02","3.02","3.03","5.02","7.01","9.01"],"status":"ready","headline":"Ocuphire completes merger with Opus Genetics; renamed Opus Genetics with $37M pro forma cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed Oct 22; Ocuphire issued ~5.24M common shares and 14,145 Series A Preferred (convertible into ~14.1M common) to Opus securityholders.","Pro forma cash ~$37M as of Sep 30, 2024; cash runway expected into 2026.","Name changed to Opus Genetics, Inc. effective Oct 23; ticker begins trading as 'IRD' on Oct 24, 2024.","Dr. Benjamin Yerxa appointed President; base salary $425,000, 35% target bonus, 332,800 RSUs; Board expanded to 9.","180-day lock-up agreements on shares held by certain stockholders and all directors/officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204112,"accession_number":"0001140361-24-036944","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ocuphire Q2 net loss $7.8M ($0.30/sh); cash $41.4M; VEGA-3 recruiting for presbyopia","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.8M ($0.30/sh) vs $5.0M ($0.24) in Q2 2023; revenue from collaborator license $1.1M vs $3.7M.","Cash $41.4M provides runway into mid-2025; R&D spend $6.1M (+30% YoY) driven by APX3330 manufacturing.","VEGA-3 Phase 3 trial of phentolamine ophthalmic solution 0.75% for presbyopia now recruiting; topline 2025.","LYNX-2 Phase 3 study for dim light disturbances enrollment strong; LYNX-3 study planned for 2024.","Discussions with FDA ongoing for APX3330 Special Protocol Assessment in diabetic retinopathy."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":2823000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220825,"accession_number":"0001140361-24-030012","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Ocuphire Pharma shareholders approve share increase to 125M, reject Lincoln Park issuance and officer exculpation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to increase authorized common stock from 75M to 125M, effective June 12.","Shareholders rejected proposed issuance of shares to Lincoln Park Capital in excess of 19.99% of outstanding.","Shareholders rejected charter amendment to exculpate officers.","Board adopted amended bylaws with enhanced procedural rules for stockholder nominations and proposals.","All seven director nominees elected; Ernst & Young ratified as auditor; say-on-pay advisory approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220824,"accession_number":"0001140361-24-025476","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Ocuphire Pharma presents NPDR subset analysis from ZETA-1 Phase 2 trial for APX3330","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Subset analysis: 3% of APX3330 vs 20% of placebo had ≥3-step worsening on binocular DRSS at Week 24.","7% of APX3330 vs 27% of placebo developed PDR (DRSS ≥61) in either eye at Week 24.","APX3330 was well-tolerated; ocular AEs similar between groups, pruritus mild/self-limited.","NPDR subset includes moderate-to-severe NPDR patients without CI-DME at baseline.","Results inform planned trial of APX3330 to slow PDR conversion in high-risk NPDR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220823,"accession_number":"0001140361-24-025329","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ocuphire Q1 net loss $7.1M ($0.29/sh); cash $47.2M; RYZUMVI launch yields first royalty","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.1M ($0.29 per share) vs $5.8M ($0.28) in Q1 2023.","Cash and equivalents $47.2M; management expects funding into mid-2025.","License revenue flat at $1.7M; first RYZUMVI royalty of $3,000 recognized.","Partner Viatris launched RYZUMVI in April 2024; LYNX-2 Phase 3 trial enrolled first subject.","FDA SPA dialogue for APX3330 Phase 2/3 DR trial ongoing; timing of agreement TBD."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":1711000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220822,"accession_number":"0001140361-24-020320","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2024-04-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ocuphire Pharma awards director Dr. Pepose $39,583/mo consulting fee, 32K RSUs and 48K options at $1.79","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Monthly consulting fee of $39,583 for Dr. Jay Pepose, an existing director, effective April 11, 2024.","Grant of 32,000 restricted stock units vesting on April 11, 2025, subject to continued service.","Options to purchase 48,000 shares at $1.79 (closing price on grant date), vesting in 12 monthly installments.","Agreement terminates on April 11, 2025, unless extended by mutual written agreement.","Consulting services in the field of ophthalmology; Dr. Pepose remains an independent contractor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240428,"accession_number":"0001140361-24-015624","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Ocuphire shares investor presentation; no material new details available","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished investor presentation under Regulation FD for March 2024 meetings.","Exhibit 99.1 content is incomplete; no specific financial or operational updates provided.","Presentation intended for routine investor outreach; no material changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240427,"accession_number":"0001140361-24-012128","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ocuphire Pharma reports FY 2023 net loss of $10M; advances APX3330 Phase 3 and RYZUMVI launch","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $50.5M at Dec 31, 2023; management expects to fund operations into mid-2025.","FY 2023 revenue $19.0M (incl. $10M Viatris milestone) vs $39.9M in 2022; net loss $10.0M ($0.46/share) vs net income $17.9M in 2022.","APX3330 SPA submitted for Phase 3 registrational trial in diabetic retinopathy; FDA agreed on primary endpoint.","RYZUMVI (phentolamine) approved Sep 2023; launch expected H1 2024; Viatris to fund further development for presbyopia and post-refractive surgery.","Leadership changes: George Magrath CEO (Nov 2023), new CFO and CSDO appointed Feb 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240426,"accession_number":"0001140361-24-008352","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2024-02-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ocuphire Pharma appoints Nirav Jhaveri as CFO and Ash Jayagopal as Chief Scientific Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nirav Jhaveri appointed CFO effective Feb 12, 2024; base salary $410k, equity awards: 210k options + 140k RSUs.","Ash Jayagopal appointed Chief Scientific and Development Officer; 15+ years retinal disease experience, previously at Opus Genetics and Roche.","Jhaveri previously CFO at Insilico Medicine and Journey Medical; over 20 years biopharma finance experience.","Both appointments effective Feb 12, 2024, as company advances APX3330 phase 3 in diabetic retinopathy.","Jhaveri eligible for discretionary annual cash bonus up to 45% of base salary; severance includes 0.75x salary plus prorated bonus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257949,"accession_number":"0001140361-23-056425","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2023-12-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ocuphire promotes Ronil Patel to Chief Business Officer; grants 74K options and 50K RSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ronil Patel, age 40, promoted to Chief Business Officer effective December 1, 2023; previously SVP of Operations and Business Development.","Base salary set at $350,000, increasing to $400,000 upon meeting certain milestones (e.g., $100M cash balance or strategic term sheet).","Eligible for annual bonus targeted at 45% of base salary (up from 40%).","Granted incentive stock option to purchase 74,538 shares and RSU for 49,692 shares, vesting over ~2.5 years.","Background: 15 years experience; involved in deals over $300M; previously at Point Guard Partners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257948,"accession_number":"0001140361-23-054632","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2023-11-27T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Ocuphire Pharma appoints Joseph Schachle COO; $400K salary, 300K option grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph Schachle appointed COO effective Nov 27, 2023; previously COO of Opus Genetics.","Base salary $400K, target annual bonus 45% of base, 300K stock option grant.","Stock option vests 25% on 1-year anniversary, remaining monthly over 36 months.","Appointment part of strategic initiative to advance lead retina asset APX3330 into registrational studies.","Severance: 9 months salary continuation plus COBRA reimbursement if terminated without cause or for good reason."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257947,"accession_number":"0001140361-23-052736","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ocuphire Q3 net income $5.6M ($0.26 EPS); revenue $11.9M; FDA agrees Phase 3 endpoint for APX3330; RYZUMVI approved","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net income $5.6M ($0.26 basic EPS) vs $4.5M loss ($0.22 loss) a year ago; revenue $11.9M from $0.","Cash $42.4M; management believes sufficient into 2025.","Successful End-of-Phase 2 FDA meeting for APX3330; Phase 3 endpoint agreed (3-step worsening on DRSS).","RYZUMVI (phentolamine) FDA approved for mydriasis reversal; Ocuphire received $10M milestone from Viatris.","VEGA-2 Phase 3 presbyopia trial met primary endpoint; Viatris to continue Phase 3 development in 1H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":17358000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257946,"accession_number":"0001140361-23-051009","cik":1228627,"company_name":"Opus Genetics, Inc.","ticker":"IRD","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Ocuphire successful End-of-Phase 2 meeting with FDA for oral APX3330 in diabetic retinopathy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed on Phase 3 primary endpoint: ≥3-step worsening on binocular DRSS; SPA to be submitted.","APX3330 could be first oral option for ~8M US NPDR patients; Phase 2 ZETA-1 showed slowing of DR progression.","Company plans Special Protocol Assessment to finalize trial design and timing with FDA.","Phase 2 ZETA-1 met primary endpoint: lower % of APX3330-treated patients had ≥3-step worsening vs placebo at 24 weeks.","APX3330 demonstrated favorable safety/tolerability; CEO calls it 'most advanced oral therapy in development for DR'."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":343082183.18115944,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-11-02T23:59:59+00:00|257946"}